Burning Rock Biotech Limited (BNR)
Tests cancer tumors to match patients with the right treatment drugs.
$9.09-0.03%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago+60.2%
The outlook
BNR is trading near its 52-week lows, sitting well below both its 50- and 200-day moving averages, reflecting a downward price trend. The stock sits roughly 10% of the way up from its yearly low, suggesting it remains in a depressed position within its annual range. Analyst coverage appears thin, and the overall sentiment is bearish based on current technical positioning.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Market cap
$95.8M
52-wk high
$41.72
52-wk low
$5.31
50-day avg
$10.37
200-day avg
$17.72
Trailing P/E
—